NASDAQ:GRTS Gritstone bio (GRTS) Stock Price, News & Analysis → Could Your Accounts Be Frozen? (From Allegiance Gold) (Ad) Free grts Stock Alerts $0.96 +0.09 (+10.31%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$0.88▼$1.0050-Day Range$0.74▼$2.8452-Week Range$0.67▼$3.33Volume4.20 million shsAverage Volume3.05 million shsMarket Capitalization$103.13 millionP/E RatioN/ADividend YieldN/APrice Target$6.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Gritstone bio alerts: Email Address Gritstone bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside557.9% Upside$6.33 Price TargetShort InterestBearish13.16% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.25Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.95) to ($0.88) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.53 out of 5 starsMedical Sector4021st out of 5,424 stocksBiological Products, Except Diagnostic Industry658th out of 909 stocks 3.5 Analyst's Opinion Consensus RatingGritstone bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGritstone bio has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.16% of the float of Gritstone bio has been sold short.Short Interest Ratio / Days to CoverGritstone bio has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Gritstone bio has recently increased by 40.35%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGritstone bio does not currently pay a dividend.Dividend GrowthGritstone bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GRTS. Previous Next 2.9 News and Social Media Coverage News SentimentGritstone bio has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Gritstone bio this week, compared to 2 articles on an average week.Search Interest14 people have searched for GRTS on MarketBeat in the last 30 days. This is an increase of 27% compared to the previous 30 days.MarketBeat Follows9 people have added Gritstone bio to their MarketBeat watchlist in the last 30 days. This is an increase of 125% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Gritstone bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.61% of the stock of Gritstone bio is held by insiders.Percentage Held by Institutions48.46% of the stock of Gritstone bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Gritstone bio are expected to grow in the coming year, from ($0.95) to ($0.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gritstone bio is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gritstone bio is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGritstone bio has a P/B Ratio of 1.78. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsFW: 234x GainThis coin is an essential building block for an ongoing financial revolution of massive dimensions. As a big part of this revolution, the big banks of the world must connect to the blockchain.Click here. About Gritstone bio Stock (NASDAQ:GRTS)Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.Read More GRTS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GRTS Stock News HeadlinesMay 2, 2024 | globenewswire.comGritstone bio to Report First Quarter 2024 Financial Results and Provide Corporate Updates on May 9, 2024April 29, 2024 | globenewswire.comGritstone bio Announces Appointment of Stephen Webster to its Board of DirectorsMay 4, 2024 | Stansberry Research (Ad)Global crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...April 20, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTSApril 15, 2024 | finance.yahoo.comNature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)April 15, 2024 | globenewswire.comNature Medicine Publishes Interim Results from Gritstone bio's Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)April 12, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTSApril 10, 2024 | stockhouse.comGritstone bio Presents Improvements to EDGE(TM) Platform at AACR 2024May 4, 2024 | Stansberry Research (Ad)Global crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...April 8, 2024 | markets.businessinsider.comBuy Rating Affirmed: Gritstone Oncology’s Promising Growth and Technological AdvancementsApril 8, 2024 | finance.yahoo.comGritstone bio Presents Improvements to EDGE™ Platform at AACR 2024April 4, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTSApril 3, 2024 | benzinga.comGritstone Bio Stock (NASDAQ:GRTS), Quotes and News SummaryApril 2, 2024 | markets.businessinsider.comNasdaq Down Over 1%; VivoPower International Shares Spike HigherApril 2, 2024 | msn.comWhat's Going On With Small Cap Cancer Vaccine Focused Gritstone Bio Stock On Tuesday?April 2, 2024 | investorplace.comWhy Are Health Insurance Stocks HUM, UNH, CI Down Today?April 2, 2024 | marketwatch.comGritstone Bio Shares Drop 33% After Public Offering PricesApril 2, 2024 | investorplace.comWhy Is Gritstone Bio (GRTS) Stock Down 44% Today?April 1, 2024 | globenewswire.comGritstone bio Announces Pricing of $32.5 Million Underwritten Public OfferingApril 1, 2024 | msn.comGritstone stock plunges 35% on mixed Phase 2 data, public offeringApril 1, 2024 | globenewswire.comGritstone bio Announces Proposed Public OfferingApril 1, 2024 | globenewswire.comGritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)March 28, 2024 | seekingalpha.comGRTS Gritstone bio, Inc.March 19, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTSMarch 18, 2024 | msn.comDo Options Traders Know Something About Gritstone bio (GRTS) Stock We Don't?March 8, 2024 | finance.yahoo.comGritstone bio, Inc. (NASDAQ:GRTS) Just Reported And Analysts Have Been Cutting Their EstimatesMarch 7, 2024 | finance.yahoo.comGritstone Bio Inc (GRTS) Reports Fiscal Year 2023 Financial Results and Corporate UpdatesSee More Headlines Receive GRTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gritstone bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today5/04/2024Next Earnings (Confirmed)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:GRTS CUSIPN/A CIK1656634 Webwww.gritstoneoncology.com Phone(510) 871-6100FaxN/AEmployees231Year FoundedN/APrice Target and Rating Average Stock Price Target$6.33 High Stock Price Target$7.00 Low Stock Price Target$5.00 Potential Upside/Downside+557.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-138,490,000.00 Net Margins-847.24% Pretax Margin-847.34% Return on Equity-147.22% Return on Assets-69.46% Debt Debt-to-Equity Ratio0.77 Current Ratio3.20 Quick Ratio3.20 Sales & Book Value Annual Sales$16.34 million Price / Sales6.31 Cash FlowN/A Price / Cash FlowN/A Book Value$0.54 per share Price / Book1.78Miscellaneous Outstanding Shares107,130,000Free Float102,192,000Market Cap$103.13 million OptionableOptionable Beta0.64 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Andrew R. Allen BCh (Age 58)BM, M.D., MA, MRCP, Ph.D., Co-Founder, President, CEO & Director Comp: $983.44kMr. Erin E. Jones M.S. (Age 52)Executive VP & COO Comp: $658.01kDr. Karin Jooss Ph.D. (Age 58)Executive VP and Head of Research & Development Comp: $706.07kMs. Vassiliki Economides (Age 43)Executive VP & CFO Mr. James ChoChief Accounting OfficerGeorge MacDougallDirector of Investor Relations & Corporate CommunicationsMs. Stacy ProctorExecutive VP & Chief People OfficerDr. Matthew J. Hawryluk M.B.A. (Age 45)Ph.D., Executive VP & Chief Business Officer More ExecutivesKey CompetitorsCEL-SCINYSE:CVMPassage BioNASDAQ:PASGAthira PharmaNASDAQ:ATHAAtara BiotherapeuticsNASDAQ:ATRACognition TherapeuticsNASDAQ:CGTXView All CompetitorsInsiders & InstitutionsBNP Paribas Financial MarketsBought 21,271 shares on 5/1/2024Ownership: 0.047%Klingman & Associates LLCBought 34,786 shares on 5/1/2024Ownership: 0.035%Frazier Life Sciences Management L.P.Sold 400,000 shares on 2/15/2024Ownership: 1.081%Panagora Asset Management Inc.Sold 10,350 shares on 2/8/2024Ownership: 0.211%Forum Financial Management LPBought 72,201 shares on 2/7/2024Ownership: 0.094%View All Insider TransactionsView All Institutional Transactions GRTS Stock Analysis - Frequently Asked Questions Should I buy or sell Gritstone bio stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gritstone bio in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GRTS shares. View GRTS analyst ratings or view top-rated stocks. What is Gritstone bio's stock price target for 2024? 3 brokers have issued 12-month target prices for Gritstone bio's shares. Their GRTS share price targets range from $5.00 to $7.00. On average, they expect the company's share price to reach $6.33 in the next year. This suggests a possible upside of 557.9% from the stock's current price. View analysts price targets for GRTS or view top-rated stocks among Wall Street analysts. How have GRTS shares performed in 2024? Gritstone bio's stock was trading at $2.04 at the beginning of the year. Since then, GRTS stock has decreased by 52.8% and is now trading at $0.9627. View the best growth stocks for 2024 here. Are investors shorting Gritstone bio? Gritstone bio saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 12,800,000 shares, an increase of 40.4% from the March 31st total of 9,120,000 shares. Based on an average daily volume of 2,880,000 shares, the days-to-cover ratio is currently 4.4 days. Currently, 13.2% of the shares of the company are sold short. View Gritstone bio's Short Interest. When is Gritstone bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our GRTS earnings forecast. How can I listen to Gritstone bio's earnings call? Gritstone bio will be holding an earnings conference call on Thursday, May 9th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Gritstone bio's earnings last quarter? Gritstone bio, Inc. (NASDAQ:GRTS) released its quarterly earnings results on Tuesday, March, 5th. The company reported ($0.26) earnings per share for the quarter, topping analysts' consensus estimates of ($0.36) by $0.10. The firm earned $10.38 million during the quarter, compared to the consensus estimate of $4.80 million. Gritstone bio had a negative trailing twelve-month return on equity of 147.22% and a negative net margin of 847.24%. What ETF holds Gritstone bio's stock? Morningstar US Small Growth holds 23,628 shares of GRTS stock, representing 2.17% of its portfolio. What is Andrew Allen's approval rating as Gritstone bio's CEO? 1 employees have rated Gritstone bio Chief Executive Officer Andrew Allen on Glassdoor.com. Andrew Allen has an approval rating of 100% among the company's employees. This puts Andrew Allen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Gritstone bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Gritstone bio investors own include ADMA Biologics (ADMA), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Novan (NOVN), Sorrento Therapeutics (SRNE), Zosano Pharma (ZSAN), Enerplus (ERF), Oncolytics Biotech (ONCY), SCYNEXIS (SCYX) and CBL & Associates Properties (CBL). When did Gritstone bio IPO? Gritstone bio (GRTS) raised $85 million in an initial public offering on Friday, September 28th 2018. The company issued 6,100,000 shares at $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays acted as the underwriters for the IPO and BTIG was co-manager. Who are Gritstone bio's major shareholders? Gritstone bio's stock is owned by a variety of institutional and retail investors. Top institutional investors include BNP Paribas Financial Markets (0.05%) and Klingman & Associates LLC (0.04%). Insiders that own company stock include Erin Jones and Vassiliki Economides. View institutional ownership trends. How do I buy shares of Gritstone bio? Shares of GRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GRTS) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchStock-Picking AI Predicts #1 Stock of 2024AltimetryHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceThe asset beating inflation by 4xColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gritstone bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
